Phlow secures $20 million to advance manufacturing initiatives in the US
The company seeks to actively accelerate US manufacturing for medicines at risk of shortage, including those for COVID-19 pandemic response
Pharma start-up Phlow Corporation has announced it has secured $20 million in a recent round of financing and said it will use the money to establish a commercial team, build data and analytics platforms, press on with commercial R&D of active pharmaceutical ingredients (APIs) and finished products, as well as funding other plans to deliver essential medicines.
Phlow, which was established to address the US supply chain's heavy dependence upon foreign suppliers, is using advanced manufacturing processes leveraging flow chemistry to produce active pharmaceutical ingredients (APIs) and finished pharmaceutical products, including those for COVID-19 pandemic response.
In May 2020, Phlow bagged a contract to manufacture generics and APIs in shortage, funded by Biomedical Advanced Research and Development Authority (BARDA), part of the office of Assistant Secretary for Preparedness and Response (ASPR) at the US Department of Health and Human Services (HHS).
The total contract value awarded to Phlow could reach $812 million; an initial four-year base award of $354 million with an additional $458 million bundled in as potential options for long-term sustainability. Under the terms of the agreement, Phlow is leading a team of private sector entities that includes API and intermediates manufacturer Ampac Fine Chemicals, Civica Rx and the Medicines for All Institute.
In its first contract year, Phlow said it has delivered millions of doses of essential medicines as part of a US-based, surge capacity ramp-up supporting critical COVID-19 response efforts while boosting the US's national supply chain security.
In addition, the company has developed and is operationalizing the US's first Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This long-term, national stockpile of key ingredients will be used to manufacture the most essential medicines on US soil and further reduce America's dependency on foreign nations to support its drug supply chain.
On its website, Virginia-based Phlow markets itself as a solution to a “broken” US pharmaceutical supply chain “dangerously dependent on foreign suppliers.” It says traditional batch manufacturing, which it describes as a multi-step, lengthy process that involves the use of large-scale, labour-intensive equipment, has led to API production being mainly centred in China and India, where labour costs are low.
The company says all its pharmaceutical products will be manufactured in the US by continuous manufacturing, which it describes as a modern process “that maximizes throughput, increases productivity, and lowers labour requirements.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance